Catalent's Open Letter to Customers Regarding Novo Holdings
Oct 21, 2024 · Alessandro Maselli to Remain President and CEO of Catalent Post-Close. October 21, 2024 – SOMERSET, N.J. – Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today issued the following open letter to customers: To Catalent’s Valued Customers,
News and Events - Catalent
Jul 16, 2024 · Catalent announced today that it has entered into a definitive agreement to sell its oral solids development and small-scale manufacturing facility in Somerset, NJ to Ardena, a Contract Development and Manufacturing Organization (CDMO) with locations in Belgium, Spain, the Netherlands and Sweden.
Catalent and Novo Holdings Receive Clearances for Transaction
SOMERSET, NJ and COPENHAGEN, Denmark – December 14, 2024 – Catalent, Inc. (“Catalent,” NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings A/S (“Novo Holdings”), a global life sciences investment firm, today announced that the companies have fulfilled all ...
Novo Holdings to Acquire Catalent
Feb 5, 2024 · Catalent and Novo Holdings have entered into a merger agreement in an all-cash transaction that values Catalent at $16.5 billion. Catalent Stockholders to Receive $63.50 Per Share in Cash, Representing a 47.5% Premium to the 60-day Volume-Weighted Average Price as of February 2, 2024
Catalent Signs Agreement to Sell Somerset, NJ Oral Solids Facility
Oct 14, 2024 – Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, announced today that it has entered into a definitive agreement to sell its oral solids development and small-scale manufacturing facility in Somerset, NJ to Ardena, a Contract Development and ...
Novo Holdings Completes Acquisition of Catalent
Catalent’s common stock has ceased trading and will be delisted from the New York Stock Exchange. Shortly following the completion of the transaction, Novo Nordisk A/S will acquire from Novo Holdings Catalent’s three fill-finish sites located in Anagni, Italy; Bloomington, Indiana, USA; and Brussels, Belgium, and related assets.
Catalent Announces New Operating Structure
Jul 5, 2022 · Catalent's new organizational structure includes a shift from four reporting segments to two, each representing roughly half of the total company revenue.
Catalent & Novo Holdings Receive EC Approval for Transaction
“We are pleased to have received European Commission approval, which is a significant milestone toward completing our pending transaction with Novo Holdings,” said Alessandro Maselli, President and Chief Executive Officer of Catalent. “I am deeply grateful for the ongoing commitment and efforts of the Catalent team.
News Details - Catalent
Aug 29, 2023 · Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply around 80 billion doses of nearly 8,000 products annually. Catalent’s expert workforce of approximately 18,000 includes more than 3,000 scientists and technicians.
Catalent Stockholders Approve Transaction with Novo Holdings
May 29, 2024 · Catalent, Inc. (“Catalent,” NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, today announced that, at its Special Meeting of Stockholders (the “Special Meeting”) held earlier today, its stockholders voted to approve the pending transaction under which Novo Holdings A/S (“Novo ...